晚期卵巢癌的巩固或维持治疗

doi:10.3760/cma.j.issn.1673-422X.2014.01.019

国际肿瘤学杂志 ›› 2014, Vol. 41 ›› Issue (1): 60-62.doi: 10.3760/cma.j.issn.1673-422X.2014.01.019

晚期卵巢癌的巩固或维持治疗

夏婷,于爱军

310022杭州，浙江省肿瘤医院妇瘤科

出版日期:2014-01-08 发布日期:2014-01-22
通讯作者: 于爱军，E-mail：yaj1993@126.com E-mail:yaj1993@126.com

Consolidation or maintenance therapy for advanced ovarian cancer

Xia Ting, Yu Aijun

Department of Gynecologic Oncology, Zhejiang Cancer Hospital, Hangzhou 310022, China

Online:2014-01-08 Published:2014-01-22
Contact: Yu Aijun E-mail:yaj1993@126.com

摘要/Abstract

摘要： 对初次标准治疗后达到完全缓解的卵巢癌患者给予巩固治疗或维持治疗，可以延缓复发。巩固或维持治疗的方案有化疗、放疗及生物治疗。临床试验证实，上述治疗方案各有优缺点，临床疗效也不尽相同。目前学者还在寻找新的巩固治疗方案，为延缓或预防卵巢癌复发提供最佳治疗途径。

关键词: 卵巢肿瘤, 治疗结果, 巩固治疗

Abstract: Consolidation therapy or maintenance therapy for complete response to conventional treatment can delay recurrence of ovarian cancer. Consolidation or maintenance therapy programs include chemotherapy, radiotherapy and biological treatment. Clinical trials confirm that these treatment agents have their advantages and disadvantages, and the effects are quite different. Now scientists are still exploring new agents, for finding the best pathway to delay or even prevent recurrence.

Key words: Ovarian neoplasms, Treatment outcome, Consolidation therapy

夏婷,于爱军. 晚期卵巢癌的巩固或维持治疗[J]. 国际肿瘤学杂志, 2014, 41(1): 60-62.

Xia Ting, Yu Aijun. Consolidation or maintenance therapy for advanced ovarian cancer[J]. Journal of International Oncology, 2014, 41(1): 60-62.

参考文献

［1］ Ozols RF. Maintenance therapy in advanced ovarian cancer: progressionfree survival and clinical benefit［J］. J Clin Oncol, 2003, 21(13):24512453. ［2］ Markman M, Liu PY, Wilczynski S, et al. Phase Ⅲ randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxelbased chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group Trial［J］. J Clin Oncol, 2003, 21(13):24602465. ［3］ Markman M, Liu PY, Moon J, et al. Impact on survival of 12 versus 3 monthly cycles of paclitaxel (175 mg/m2) administered to patients with advanced ovarian cancer who attained a complete response to primary platinumpaclitaxel: followup of a Southwest Oncology Group and Gynecologic Oncology Group phase 3 trial［J］. Gynecol Oncol, 2009, 114(2):195198. ［4］ Pecorelli S, Favalli G, Gadducci A, et al. Phase Ⅲ trial of observation versus six courses of paclitaxel in patients with advanced epithelial ovarian cancer in complete response after six courses of paclitaxel/platinumbased chemotherapy: final results of the after6 protocol 1［J］. J Clin Oncol, 2009, 27(28):46424648. ［5］ De Placido S, Scambia G, Di Vagno G, et al. Topotecan compared with no therapy after response to surgery and carboplatin/paelitaxel in patients with ovarian cancer: multicenter italian trials in ovarian cancer (M1TO1) randomized study［J］. J Clin Oncol, 2004, 22(13):26352642. ［6］ Kim JH, Lee JM, Ryu KS, et al. Consolidation hyperthermic intraperitoneal chemotherapy using paclitaxel in patients with epithelial ovarian cancer［J］. J Surg Oncol, 2010, 101(2):149155. ［7］ Sorbe B. Consolidation treatment of advanced ovarian carcinoma with radiotherapy after induction chemotherapy［J］. Int J Gynecol Cancer, 2003, 13 Suppl 2:192195. ［8］ Berek J, Taylor P, McGuire W, et al. Oregovomab maintenance monoimmunotherapy does not improve outcomes in advanced ovarian cance［J］. J Clin Oncol, 2009, 27(3):418425. ［9］ Burger RA, Brady MF, Bookman MA, et al. Incorporation of bevacizumab in the primarytreatment of ovarian cancer［J］. N Engl J Med, 2011, 365(26):24732483. ［10］ Perren TJ, Swart AM, Pfisterer J, et al. A phase 3 trial of bevacizumab in ovarian cancer［J］. N Engl J Med, 2011, 365(26):24842496.

[1]	钱晓涛, 石子宜, 胡格, 吴晓维. Ⅲ~ⅣA期食管鳞状细胞癌放化疗后行巩固化疗的疗效：一项真实世界临床研究[J]. 国际肿瘤学杂志, 2024, 51(6): 326-331.
[2]	王昆, 周中新, 臧其威. 血清TGF-β1、VEGF水平对非小细胞肺癌患者单孔胸腔镜根治术后复发的预测价值[J]. 国际肿瘤学杂志, 2024, 51(4): 198-203.
[3]	严爱婷, 王翠竹, 刘春桂, 鲁小敏. 卡瑞利珠单抗与信迪利单抗治疗晚期非小细胞肺癌的临床疗效及安全性分析[J]. 国际肿瘤学杂志, 2024, 51(3): 137-142.
[4]	龚艳, 陈洪雷. 微RNA调控卵巢癌顺铂耐药的机制研究进展[J]. 国际肿瘤学杂志, 2024, 51(3): 186-190.
[5]	姜溪, 武永存, 梁艳, 楚丽, 段颖欣, 王力军, 霍俊杰. 派安普利单抗联合化疗对晚期非小细胞肺癌患者血管生成及循环内皮细胞的影响[J]. 国际肿瘤学杂志, 2024, 51(2): 89-94.
[6]	高新雨, 李振江, 孙洪福, 韩丹, 赵倩, 刘成新, 黄伟. 基于MR加速器的MR引导放疗在食管癌患者中的临床应用[J]. 国际肿瘤学杂志, 2024, 51(1): 37-42.
[7]	安荣, 刘美华, 王佩晨, 王晓慧. Nrf2在卵巢癌中的研究进展[J]. 国际肿瘤学杂志, 2023, 50(8): 493-497.
[8]	李晨曦, 赵宏伟. 二次肿瘤细胞减灭术治疗初始减瘤手术不满意铂敏感复发性卵巢癌的预后及影响因素分析[J]. 国际肿瘤学杂志, 2023, 50(6): 342-347.
[9]	杨丽蓉, 王羽丰. 预测浆液性卵巢癌术后复发远处转移风险机器学习模型的构建[J]. 国际肿瘤学杂志, 2023, 50(4): 220-226.
[10]	周婷, 徐少华, 梅林. 贝伐珠单抗联合卡培他滨治疗晚期乳腺癌的有效性及安全性[J]. 国际肿瘤学杂志, 2023, 50(3): 144-149.
[11]	曹梦清, 徐志勇, 施毓婷, 王凯. 三级淋巴结构在肿瘤免疫微环境调节和抗肿瘤治疗中的作用[J]. 国际肿瘤学杂志, 2023, 50(3): 169-173.
[12]	王冰, 王爱馥, 刘雯舒, 范娇娇, 田伟成, 王玮莉, 刘博宇. 重组人血小板生成素治疗肿瘤放疗所致血小板减少症的疗效及安全性[J]. 国际肿瘤学杂志, 2023, 50(11): 661-667.
[13]	卢鑫, 姜军. 安罗替尼治疗晚期恶性肿瘤的近期疗效和安全性[J]. 国际肿瘤学杂志, 2022, 49(9): 572-574.
[14]	刘松, 于广计, 王庆东. DEBIRI-TACE联合瑞戈非尼三线以上治疗结直肠癌肝转移的疗效及影响因素分析[J]. 国际肿瘤学杂志, 2022, 49(7): 400-407.
[15]	蔡刚祥, 李境, 许斌. 肺癌新辅助免疫治疗研究进展[J]. 国际肿瘤学杂志, 2022, 49(6): 366-370.

晚期卵巢癌的巩固或维持治疗

Consolidation or maintenance therapy for advanced ovarian cancer

PDF

可视化

被引次数

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价